CLIMB BIO INC (CLYM) Stock Price, Quote, News and Overview
NASDAQ:CLYM - Nasdaq - US28658R1068 - Common Stock - Currency: USD
CLYM Quote, Performance and Key Statistics
1.34
+0.08 (+6.35%)
The current stock price of CLYM is 1.34 USD. In the past month the price increased by 11.67%.
CLYM Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19 | 345.13B | ||
| AMGN | AMGEN INC | 14.68 | 156.41B | ||
| GILD | GILEAD SCIENCES INC | 13.76 | 132.82B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1756.9 | 130.98B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.51 | 65.46B | ||
| ARGX | ARGENX SE - ADR | 339.55 | 39.39B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.24B | ||
| ONC | BEIGENE LTD-ADR | N/A | 28.00B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.04B | ||
| NTRA | NATERA INC | N/A | 20.40B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.79B | ||
| BIIB | BIOGEN INC | 7.35 | 17.72B |
Related stock screener links
About CLYM
Company Profile
Climb Bio, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 17 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The firm is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).
Company Info
CLIMB BIO INC
20 William Street, Suite 145
Wellesley Hills MASSACHUSETTS US
Employees: 17
Company Website: https://climbbio.com/
Investor Relations: https://ir.eliemtx.com/
Phone: 18668572596
CLIMB BIO INC / CLYM FAQ
What is the stock price of CLIMB BIO INC today?
The current stock price of CLYM is 1.34 USD. The price increased by 6.35% in the last trading session.
What is the ticker symbol for CLIMB BIO INC stock?
The exchange symbol of CLIMB BIO INC is CLYM and it is listed on the Nasdaq exchange.
On which exchange is CLYM stock listed?
CLYM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for CLIMB BIO INC stock?
7 analysts have analysed CLYM and the average price target is 10.2 USD. This implies a price increase of 661.19% is expected in the next year compared to the current price of 1.34. Check the CLIMB BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is CLIMB BIO INC worth?
CLIMB BIO INC (CLYM) has a market capitalization of 90.42M USD. This makes CLYM a Micro Cap stock.
How many employees does CLIMB BIO INC have?
CLIMB BIO INC (CLYM) currently has 17 employees.
What are the support and resistance levels for CLIMB BIO INC (CLYM) stock?
CLIMB BIO INC (CLYM) has a support level at 1.22 and a resistance level at 1.35. Check the full technical report for a detailed analysis of CLYM support and resistance levels.
Should I buy CLIMB BIO INC (CLYM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of CLYM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of CLYM, evaluating the profitability, health, valuation and growth aspects
- CLIMB BIO INC (CLYM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- CLIMB BIO INC (CLYM) Sales and EPS estimates to see what analysts future expectations are.
- CLIMB BIO INC (CLYM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- CLIMB BIO INC (CLYM) Insider and Institutional Ownership to learn about the owners and their transactions.
- CLIMB BIO INC (CLYM) Stock Chart to make your own analysis
- CLIMB BIO INC (CLYM) Latest news and press-releases to stay up to date.
Does CLIMB BIO INC (CLYM) stock pay dividends?
CLYM does not pay a dividend.
When does CLIMB BIO INC (CLYM) report earnings?
CLIMB BIO INC (CLYM) will report earnings on 2025-05-19.
What is the Price/Earnings (PE) ratio of CLIMB BIO INC (CLYM)?
CLIMB BIO INC (CLYM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.72).
What is the Short Interest ratio of CLIMB BIO INC (CLYM) stock?
The outstanding short interest for CLIMB BIO INC (CLYM) is 3.8% of its float. Check the ownership tab for more information on the CLYM short interest.
CLYM Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to CLYM.
CLYM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to CLYM. CLYM has a great financial health rating, but its profitability evaluates not so good.
CLYM Financial Highlights
Over the last trailing twelve months CLYM reported a non-GAAP Earnings per Share(EPS) of -1.72. The EPS decreased by -62.56% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -34.02% | ||
| ROE | -34.88% | ||
| Debt/Equity | 0 |
CLYM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to CLYM. The Buy consensus is the average rating of analysts ratings from 7 analysts.